In search of value $SANA:
This is a look at the valuation of $SANA.
This is a look at the valuation of $SANA.
Cash = $511 million
Their first 3 programs into the clinic will all be around CD19. They have CD19 in-vivo and ex-vivo then they have CD19/CD22 bi-specific CAR-T. I think the indications would limit this to about $500 million sales unless in-vivo works really well.
Their first 3 programs into the clinic will all be around CD19. They have CD19 in-vivo and ex-vivo then they have CD19/CD22 bi-specific CAR-T. I think the indications would limit this to about $500 million sales unless in-vivo works really well.
At $500 million in sales
*.1 for just starting phase 1
=$50 million value
*.1 for just starting phase 1
=$50 million value
The next big program is islet cells for diabetes. There is expected to be upward of 1.5 million patients living with Type 1 Diabetes. I would think this would be reserved for worst case patients at least at first.
Even if they could manufacture 15,000 doses a year @ $250,000 per, that comes to $3.75 billion a year. That is where I would start.
*.1 for preclinic
$375 million value.
*.1 for preclinic
$375 million value.
All in, I get to $936 million valuation. They have about 191 million shares outstanding. This would put their value around $4.90. That puts it at about fairly valued until we get some data.
Loading suggestions...